JP2012508275A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508275A5
JP2012508275A5 JP2011536412A JP2011536412A JP2012508275A5 JP 2012508275 A5 JP2012508275 A5 JP 2012508275A5 JP 2011536412 A JP2011536412 A JP 2011536412A JP 2011536412 A JP2011536412 A JP 2011536412A JP 2012508275 A5 JP2012508275 A5 JP 2012508275A5
Authority
JP
Japan
Prior art keywords
disorder
disease
composition
disorders
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011536412A
Other languages
English (en)
Japanese (ja)
Other versions
JP5087171B2 (ja
JP2012508275A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063816 external-priority patent/WO2010056644A1/en
Publication of JP2012508275A publication Critical patent/JP2012508275A/ja
Publication of JP2012508275A5 publication Critical patent/JP2012508275A5/ja
Application granted granted Critical
Publication of JP5087171B2 publication Critical patent/JP5087171B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011536412A 2008-11-11 2009-11-10 5−ヒドロキシトリプタミン−6リガンドとしての1−(アリールスルホニル)−4−(ピペラジン−1−イル)−1h−ベンズイミダゾール類 Expired - Fee Related JP5087171B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11
US61/113,296 2008-11-11
PCT/US2009/063816 WO2010056644A1 (en) 2008-11-11 2009-11-10 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS

Publications (3)

Publication Number Publication Date
JP2012508275A JP2012508275A (ja) 2012-04-05
JP2012508275A5 true JP2012508275A5 (enExample) 2012-07-19
JP5087171B2 JP5087171B2 (ja) 2012-11-28

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536412A Expired - Fee Related JP5087171B2 (ja) 2008-11-11 2009-11-10 5−ヒドロキシトリプタミン−6リガンドとしての1−(アリールスルホニル)−4−(ピペラジン−1−イル)−1h−ベンズイミダゾール類

Country Status (41)

Country Link
US (1) US8063053B2 (enExample)
EP (1) EP2285784B1 (enExample)
JP (1) JP5087171B2 (enExample)
KR (1) KR101323417B1 (enExample)
CN (1) CN102209713B (enExample)
AP (1) AP2814A (enExample)
AR (1) AR074325A1 (enExample)
AU (1) AU2009314221B2 (enExample)
BR (1) BRPI0920682A2 (enExample)
CA (1) CA2740262C (enExample)
CL (1) CL2011001050A1 (enExample)
CO (1) CO6440548A2 (enExample)
CR (1) CR20110247A (enExample)
CU (1) CU24020B1 (enExample)
CY (1) CY1113025T1 (enExample)
DK (1) DK2285784T3 (enExample)
DO (1) DOP2011000130A (enExample)
EA (1) EA018369B1 (enExample)
EC (1) ECSP11011045A (enExample)
ES (1) ES2389694T3 (enExample)
GE (1) GEP20135805B (enExample)
HR (1) HRP20120561T1 (enExample)
IL (1) IL212213A0 (enExample)
MA (1) MA32788B1 (enExample)
ME (1) ME01129B (enExample)
MX (1) MX2011004996A (enExample)
MY (1) MY156324A (enExample)
NI (1) NI201100093A (enExample)
NZ (1) NZ592563A (enExample)
PE (1) PE20120026A1 (enExample)
PL (1) PL2285784T3 (enExample)
PT (1) PT2285784E (enExample)
RS (1) RS52381B (enExample)
SA (1) SA109300673B1 (enExample)
SI (1) SI2285784T1 (enExample)
SV (1) SV2011003902A (enExample)
TN (1) TN2011000203A1 (enExample)
TW (1) TWI481605B (enExample)
UA (1) UA100192C2 (enExample)
WO (1) WO2010056644A1 (enExample)
ZA (1) ZA201103283B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101521A2 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0515477A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
US7951805B2 (en) * 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8071603B2 (en) * 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN104557726B (zh) * 2013-10-19 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
WO2021021951A1 (en) 2019-07-29 2021-02-04 Vanderbilt University Wdr5-myc inhibitors
MX2022012828A (es) * 2020-04-22 2023-01-04 Recurium Ip Holdings Llc Preparación de un degradador selectivo de receptores de estrógeno.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0994862B1 (en) * 1997-07-11 2005-06-01 SmithKline Beecham plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
ES2193607T3 (es) * 1998-01-16 2003-11-01 Hoffmann La Roche Derivados de benzosulfona .
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
CN100396675C (zh) * 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
IL154685A0 (en) * 2000-10-20 2003-09-17 Biovitrum Ab 2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
NZ525592A (en) * 2000-11-02 2004-07-30 Wyeth Corp 1-Aryl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1401812B1 (en) * 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5-ht6受体亲和力的4-哌嗪基吲哚衍生物
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US7122665B2 (en) 2002-10-15 2006-10-17 Synta Pharmaceuticals Corp. Heterocyclic compounds
EP1737845A4 (en) 2004-04-13 2010-07-21 Synta Pharmaceuticals Corp DISPLAY HEMMER OF IL-12 PRODUCTION
RU2007107177A (ru) 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Similar Documents

Publication Publication Date Title
JP2012508275A5 (enExample)
JP2008524262A5 (enExample)
JP2015514677A5 (enExample)
JP2009538867A5 (enExample)
JP2007516941A5 (enExample)
DOP2011000130A (es) 1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6
EA201071083A1 (ru) Арилсульфонилпиразолинкарбоксамидиновые производные в качестве антагонистов 5-нт
JP2002523508A5 (enExample)
JP2013519683A5 (enExample)
EA200970310A1 (ru) Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht
CA2702482A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
JP2009538869A5 (enExample)
JP2009538870A5 (enExample)
JP2008044931A5 (enExample)
MX2012010658A (es) Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
MX2009005509A (es) 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
EP1910321A4 (en) NEW COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6-MEDIATED ILLNESSES SUCH AS ALZHEIMER'S DISEASE, COGNITIVE ILLUSTRATIONS, SCHOISOPHRENIC ASSOCIATED COGNITIVE DISORDERS, OBESITAS AND PARKINSON DISEASE
JP2011515430A5 (enExample)
JP2002525280A5 (enExample)
JP2006518732A5 (enExample)
IL198926A0 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
WO2006019886A3 (en) Pyrrolo(oxo)isoquinolines as 5ht ligands
MX363632B (es) Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
JP2008526706A5 (enExample)